Tiger pharmaceutical development and clinical trials to establish a global netwo
China's CRO through transnational cooperation, support global New Drugs R & D
Hangzhou, October 9, 2008 / PRNewswire-FirstCall / – China's leading contract research organization (CRO) Tiger Medicine announced that Russia and South Korea, OCT CRO LSK two leading strategic partnerships were established, integration of resources jointly develop and establish international clinical research network. This new strategic partnership will enable Tiger to multinational pharmaceutical Pharmaceutical Industry And mainland China and innovative drug research and development institutions in the wider geographical provide a more comprehensive clinical research outsourcing services.
Tiger Medicine is currently the one of the largest CRO in the clinical trials, leading the field, with over 100 people in the international professional team and more than 150 domestic and international customers in the United States and Europe have established liaison offices and office. In the tumor, biological Vaccine Products, Hepatitis And the digestive system, cardiovascular, and infectious diseases and other fields of research and professional experience and success in achieving international well-known venture capital firms Ignition Partners injections, Tiger is in a high-speed expansion phase of medicine.
OCT is based in St. Petersburg, Russia, a well-known clinical trials focused on CRO, clinical trial network covering Russia, Ukraine and Eastern European countries. Tiger Chinese strategic cooperation will promote business development in these countries, and for more Chinese system Pharmaceutical companies Industry into Russia and Eastern Europe markets and clinical trials registration services.
LSK is also South Korea's leading CRO, headquartered in Seoul, provides comprehensive clinical research services, clinical trial network covering South Korea, Japan, Taiwan and Malaysia. Tiger Chinese strategic cooperation will enable clinical trials in the field of the Asia-Pacific region has a more extensive clinical trials network and a decisive position, including China, who wish to access the entire Asian market, pharmaceutical companies to provide more comprehensive and integrated registration and clinical test services.
The trade, multinational CRO's powerful combination of Tiger will have a better integrated medical service capabilities, geographic coverage and to undertake international multi-center clinical research capacity in a breakthrough. The OCT and the LSK value that is owned by Tiger pharmaceutical quality customer base and innovative drug R & D capabilities, hopes to share through strategic cooperation with a wide range of international clients Tiger medicine resources.
"Cross-border cooperation by China's CRO business development and service capabilities for the globalization of a breakthrough, Tiger medicine is breaking new ground, it will be very interesting attempt. Strategic cooperation is an important strategy to expand international operations, which complementary medicine Tiger International cooperation is an important part of strategy. Our goal is to become the Asia-Pacific region within three years of clinical trial one of the most outstanding CRO. "Xiao-Chun Cao, vice president of medical Tiger said," The Tiger, traditional Chinese medicine professionals is always our primary concern, strategic cooperation so that we respect international human resources represents a major step in the long run, the development of Tiger medicine will play a very important role. At the same time, Tiger face to the world's top CRO to recruit talent, the future of Tiger will be an international community. "
I am an expert from China Manufacturers, usually analyzes all kind of industries situation, such as closure hair pieces , human braiding.
Processing your request, Please wait....
